Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for PONV in Laparoscopic Cholecystectomy
NCT05439057Completed
- Sponsor
- Inje University
- Start
- Apr 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of remimazolam in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Inje University. Primary endpoint: Postoperative Nausea and Vomiting at 24 hours. Started Apr 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT05439057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439057.